Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ross Andrews

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
BMJ Open|February 3, 2018
The NICE-GUT trial protocol: a randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal childrenClaire S Waddington, Charlie McLeod, Peter Morris, et al.
BMJ Open|September 2, 2020
Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)Susanna J Lake, Sophie L Phelan, Daniel Engelman, et al.
Vaccine: X|March 8, 2021
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal <i>Haemophilus influenzae</i> protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAmanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, et al.
Plos Neglected Tropical Diseases|March 17, 2023
One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trialSusanna J Lake, Daniel Engelman, Julie Zinihite, et al.
BMJ Open|May 26, 2020
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trialVictor M Oguoma, Nicole Wilson, Kim Mulholland, et al.
Vaccines|February 26, 2022
An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study ProtocolHelen S Marshall, Prabha H Andraweera, James Ward, et al.
BMJ Open|June 23, 2019
'Links2HealthierBubs' cohort study: protocol for a record linkage study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian womenMohinder Sarna, Ross Andrews, Hannah Moore, et al.
Scientific Reports|October 29, 2021
Mapping of population disparities in the cholangiocarcinoma urinary metabolomeMunirah Alsaleh, Zoe Leftley, Thomas O'Connor, et al.
The Lancet. Infectious Diseases|June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trialsAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
BMJ Open|May 20, 2018
Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries: a protocol for a prospective observational studyJocelyn Chan, Cattram D Nguyen, Jana Y R Lai, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
BMJ Open|February 3, 2018
The NICE-GUT trial protocol: a randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal childrenClaire S Waddington, Charlie McLeod, Peter Morris, et al.
BMJ Open|September 2, 2020
Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)Susanna J Lake, Sophie L Phelan, Daniel Engelman, et al.
Vaccine: X|March 8, 2021
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal <i>Haemophilus influenzae</i> protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAmanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, et al.
Plos Neglected Tropical Diseases|March 17, 2023
One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trialSusanna J Lake, Daniel Engelman, Julie Zinihite, et al.
BMJ Open|May 26, 2020
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trialVictor M Oguoma, Nicole Wilson, Kim Mulholland, et al.
Vaccines|February 26, 2022
An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study ProtocolHelen S Marshall, Prabha H Andraweera, James Ward, et al.
BMJ Open|June 23, 2019
'Links2HealthierBubs' cohort study: protocol for a record linkage study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian womenMohinder Sarna, Ross Andrews, Hannah Moore, et al.
Scientific Reports|October 29, 2021
Mapping of population disparities in the cholangiocarcinoma urinary metabolomeMunirah Alsaleh, Zoe Leftley, Thomas O'Connor, et al.
The Lancet. Infectious Diseases|June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trialsAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
BMJ Open|May 20, 2018
Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries: a protocol for a prospective observational studyJocelyn Chan, Cattram D Nguyen, Jana Y R Lai, et al.
Pageof 6